Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Press Release Source: SCIA-Southerna CAlifornia Investment Association, Inc.
Fourteen Under-Recognized Companies Present New Opportunities This Saturday at the SCIA National Small Cap Southern California Investment Conference in Orange County
Wednesday March 30, 10:30 am ET
MONARCH BEACH, CA--(MARKET WIRE)--Mar 30, 2005 -- Southern California Investment Association, Inc. -- SCIA -- important small cap conference from 7:15 a.m. - 1 p.m. to this Saturday, April 2nd, at the Orange County Airport Hilton (800-Hiltons), 18800 MacArthur Boulevard, Irvine, CA 92612, conveniently located across from the John Wayne Airport (SNA). Registration required.
New opportunities for growth and value are presented every 15 minutes after a 7:15 a.m. breakfast reception and closes with a seated patio luncheon with the CEOs. Companies listed for the morning include: Biophan Technologies, Inc. (OTC BB:BIPH.OB - News) Pacemaker Safety Technology for MRI Patients; Chemokine Therapeutics Corp. (Other OTC:CHKT.PK - News) Chemokines & Cytokines Immune Recovery Drugs; ColorRep, Breakthrough Digital Printing Technology; DT Group, Inc., Real Estate Mortgage / Garden Apartments; E Mobile Information Technologies, Inc. (Other OTC:EMTK.PK - News) Smart Phone Wireless Added Applications/Services; Global National Communications Corporation (OTC BB:GLNC.OB - News) Consumer Electronic OEM Processing & Distribution; Halter/Pope USX China Fund, Financial Asset Management RIA/Open Mutual Fund; Mammoth Resource Partners, Inc., Appalachian Basin Aggressive Oil Development Co.; MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) Bio-Compatible Coatings for Passive & Drug Delivery; Scrip Advantage, Inc. (Other OTC:SCPV.PK - News) Gift Certificates for 200 of the Largest Retail/Service Providers; Securac Corporation (OTC BB:SECU.OB - News) Enterprise Risk Assessment & Compliance Solutions; The Solvis Group (Other OTC:QPIX.PK - News) Market Information Technology & Staffing Solutions; Trago International, Inc., New Tequila Branding Inclusive of 3 Distinct Lines; and Whole Lifestyles Corporation, Can & Jar Processed Low Mercury Fish. Presentations will be available for viewing online next week.
About Southern California Investment Association:
SCIA National Small Cap Syndicate is a comprehensive national organization developed to facilitate stock support and capital formation for small to medium listed and emerging-growth companies. The alliance consists of almost 200 member firms including NASD broker/dealers, investment and merchant bankers, investment advisors, analysts, financial service managers, market makers, venture capitalists, fund managers, investor relations, securities attorneys, media and accredited investors. This team of over 300 key industry professionals provides a wide range of services including, but not limited to, equity and debt financing, market making, mergers and acquisitions and corporate security strategies.
SCIA promotes over 100 companies yearly at their six first Saturday bi-monthly conferences and is believed to be the best in class and value offered to small cap companies on the street today. Companies desiring support or funding are encouraged to apply at least one month in advance.
SCIA promotes special Associate Sponsorship with: Value Leader, Market Wire and SCIA Conference Sponsors: Paulson Investment Company, Inc., The Largest Independent Brokerage Firm in Pacific N.W., www.paulsoninvestment.com; Preston Gates & Ellis LLP, Law Firm Committed to Diversity, www.prestongates.com; Continental Stock Transfer & Trust Co., Great Value with Flawless Executions, www.continentalstock.com; Trilogy Capital Partners, Inc., Financial & Communications Partner with Companies to Reach Full Market Value, www.trilogy-capital.com; Securities Compliance Control, LLC, Corporate SEC Compliance Consultants, Orange, CA; Trymetris Capital Management, LLC, Micro & Small Equity Hedge Fund and Co-Sponsor: Richardson & Patel LLP, Securities Law and Corporate Finance, www.richardsonpatel.com.
Seating is qualified and limited; please Register at www.sciaonline.org or call 949-922-3003.
Contact:
Please contact:
Cherry Kau
949-922-3003
--------------------------------------------------------------------------------
Source: SCIA-Southerna CAlifornia Investment Association, Inc.
Another GOOD DAY! for our little gem...
GLTA
We wish you the best shmolton,
You and yours are in our prayers today...
GLTY
Asia Pay (APYM) is Booshing at the open...
On Very Good News out today!!!
cws6--Great find! Thanks EOM
Press Release Source: Asia Payment Systems, Inc.
Asia Payment Systems Reports Growth in Transactions Processed
Wednesday March 30, 7:57 am ET
NEW YORK and BEIJING, March 30 /PRNewswire-FirstCall/ -- Asia Payment Systems, Inc. (Asia Pay) (OTC Bulletin Board: APYM - News) today announced that during February, the Dollar volume and number of transactions processed by the company's card processing systems increased significantly. Based on volume, February which is a shorter month, showed a 16% increase over January. In terms of the number of transactions, February showed a 9% increase over January.
According to Matt Mecke, President and CEO of Asia Pay, "Each month, our systems process more transactions and greater volume. Looking at the size of the market and the market's rate of growth, we're still in the very early stages of serving China and Japan's needs for reliable, secure, and rapid bankcard processing."
About Asia Payment Systems, Inc.
Asia Pay is a USA public company with offices in: Seattle, Washington; Beijing and Shenzhen in China; and in Hong Kong. Asia Pay is developing a credit card processing network that provides clearing services to merchants, oil companies, and financial institutions in China, Japan, and in related markets elsewhere in Asia.
Asia Pay's mission is to be a national provider of world-class third-party processing services in China to bankcard-accepting merchants, issuers of bank credit cards, issuers of petroleum station retail cards, and issuers of merchandise and other retail cards. Systems, hardware, and personnel are now in place as Asia Pay commences delivering service to clients.
For more information about Asia Payment Systems, Inc. (Asia Pay), please visit: http://www.asiapayinc.com .
Contact:
Matt Mecke, President and CEO
Asia Payment Systems, Inc.
Tel: 866-877-APAY
Fax: 206-470-1150
ir@asiapayinc.com
Investor Relations:
Sussex Avenue Partners
Tel. 760-918-5592
Toll-free. 866-878-7739
news@sussexavenuepartners.com
http://www.sussexavenueprofiles.com
Press Release Source: Asia Payment Systems, Inc.
Asia Payment Systems Reports Growth in Transactions Processed
Wednesday March 30, 7:57 am ET
NEW YORK and BEIJING, March 30 /PRNewswire-FirstCall/ -- Asia Payment Systems, Inc. (Asia Pay) (OTC Bulletin Board: APYM - News) today announced that during February, the Dollar volume and number of transactions processed by the company's card processing systems increased significantly. Based on volume, February which is a shorter month, showed a 16% increase over January. In terms of the number of transactions, February showed a 9% increase over January.
According to Matt Mecke, President and CEO of Asia Pay, "Each month, our systems process more transactions and greater volume. Looking at the size of the market and the market's rate of growth, we're still in the very early stages of serving China and Japan's needs for reliable, secure, and rapid bankcard processing."
About Asia Payment Systems, Inc.
Asia Pay is a USA public company with offices in: Seattle, Washington; Beijing and Shenzhen in China; and in Hong Kong. Asia Pay is developing a credit card processing network that provides clearing services to merchants, oil companies, and financial institutions in China, Japan, and in related markets elsewhere in Asia.
Asia Pay's mission is to be a national provider of world-class third-party processing services in China to bankcard-accepting merchants, issuers of bank credit cards, issuers of petroleum station retail cards, and issuers of merchandise and other retail cards. Systems, hardware, and personnel are now in place as Asia Pay commences delivering service to clients.
For more information about Asia Payment Systems, Inc. (Asia Pay), please visit: http://www.asiapayinc.com .
Contact:
Matt Mecke, President and CEO
Asia Payment Systems, Inc.
Tel: 866-877-APAY
Fax: 206-470-1150
ir@asiapayinc.com
Investor Relations:
Sussex Avenue Partners
Tel. 760-918-5592
Toll-free. 866-878-7739
news@sussexavenuepartners.com
http://www.sussexavenueprofiles.com
Biophan Files SEC Form 8-K Containing Transcript of CEO Michael Weiner's Recent Online Interview
Wednesday March 30, 6:00 am ET
CEO Discusses Company's Expansion of Intellectual Property Portfolio in Advanced Biotechnology
ROCHESTER, N.Y.--(BUSINESS WIRE)--March 30, 2005--Biophan Technologies, Inc. (OTCBB: BIPH - News), a developer of next-generation biomedical technology, today filed an SEC Form 8-K containing the transcript of a recent online interview given by Company CEO Michael Weiner.
In the interview, Mr. Weiner states that the newly filed and issued patents are part of Biophan's continued strategy to build a market-dominating "patent thicket." These patent thickets are intended to help ensure broad protection for both the Company and for any partners that use Biophan's technology in the manufacture of biomedical solutions and products. "If someone partners with us on an exclusive basis, they'll have a really strong position to defend their market turf as we build the market together," he said.
Mr. Weiner added that Biophan's intellectual property portfolio currently represents a significant competitive advantage for the Company. Biophan's intellectual property portfolio of 114 patents, licenses, and applications includes 34 issued patents and 8 allowed applications. The Company recently filed 6 new patent applications, bringing the patents pending total to 72. The patents provide solutions to improve the safety, effectiveness, and image compatibility of medical devices used within Magnetic Resonance Imaging (MRI) environments, as well as a variety of solutions, such as nanotechnology, to create competitively advantageous product enhancements in several markets, including drug-elution technologies and implantable power systems powered by body heat. "This relates to staying several years ahead of the rest of the industry, so that as these new markets emerge for minimally invasive surgery imageable devices, we're the dominant factor in the industry," said Mr. Weiner. "That's our hope and so far we're probably over 100 patents ahead of everybody else in the industry, combined."
The two most recently issued patents can be viewed at http://www.biophan.com/6864418.html and http://www.biophan.com/6847837.html.
The interview transcript can be read in the Company's SEC Form 8-K, filed today. The audio version of the interview can be accessed at http://www.SmallcapInsights.com.
len--I'll apologize for venting such "venom",
as avould called it today. I know there's a support level in the 1.80's...It's just too much frustration building up here, so I gave the worst case scenario. And the worst case scenario is that there won't be any PR coming by Thursday's close. I guess I should have waited till that time to express these feelings, but IR has such a bad reputation for not giving what it promises, that I don't have much faith in them anymore. For example: China signed by the end of '04(though they did explain the reasoning behind that well), news that would make shareholders proud of a member of management(BA), that at least could have been sent out in an email notification for those that are signed up on the CTC website (no danger of being politically incorrect with that move)...So, I'll just shut up for now,and see what happens this week, and if no PR arrives, I will finally bail, and take what little profits I have left, until something good finally happens...
ABP--NICE Looking Chart! Overbought, but overall, NICE...MACD is looking up...It's now on my watch list...Thanks EP
Look at the volume increase on the chart in the last hour...
Maybe there's hope 2.22 doesn't get taken out "today"...
I'll make one more prediction:
If no news (as promised by IR) by the close on Thursday, the low of 2.22 will be broken, and the next stop will be 1.48
The low of 2.22 from a TA point of view was not confirmed on the chart. The bounce up to 3.10 will then be viewed as nothing more than a "dead cat bounce"...The chart IMO, is looking really bad right now...
Mr. Carswell, if you read this board, be warned that one more PR "promised", and not "delivered" will be disasterous to the morale of many shareholders, and will also be reflected in the pps. It has been way too long since we have heard "anything" from you...JMHO
ease...re: your question:
"What do you think is the biggest problem with CytRX?"
I don't really see any problem with CYTR, they are doing some very interesting research, and it's going to take a long time for this one to develop. The only way I look at this one is as a long term investment. By that, I mean "years". It sounds like you know a bit about what it is they are working on...I think they are all worthwhile projects, that if brought to successful fruition, will be a benefit to mankind , and ease a lot of suffering... If I can loan them some of my dollars to help fund their research, I think that is a worthy cause. If I in turn get rewarded by this, that's OK with me too. GLTY
So, you all think there "must" be a pullback???
Look at these two charts:
If BIPH even comes close to what BOOM has done, you may want to reconsider selling...I know I'm not selling ANY!!! Just look at what signed contracts can to do a stocks pps...
GLTA Longs,
lentinman and Bullrider:
The funny thing about hitting yourself on the head with a hammmer is: It feels soooooo good when you finally stop...
len--I agree with:
"If no news keeps not coming, then higher prices will keep not happening." (even if that is "old news" lol)
I'll still go out on a limb, and make the call that 2.22 is "The Bottom..."
That was Hilarious Rattman...ROFLMAO
I've never heard of that chart pattern, can you provide a link to that one...BTW is this a good pattern?
Willygoodshot--after a big day like today:
It's going to be hard to call what happens "tomorrow"...
We'll need a couple of days for the chart to set up some kind of pattern, and then the next "guesses" can be made. I truly feel today was THE bottom, and as I look at the chart more carefully now after the close, am almost sure of it. The last two days combined volume: today=1,544,967 (+) yesterday=741,641 totals 2,286,608 by far exceeds the 1,797,682 set on 1/25/05's low of 3.22 Todays' candlestick is a beautiful "hammer", and the stochastics have formed a nice "W", and at the close, is breaking out. We are very oversold, and have been for a very long time. All of these combined would lead me to believe we go higher for a while...Closing .08 below the 200 day MA doesn't bother me now, as I expected todays move to happen tomorrow...At this point, any buy here in this range is heaven sent, and .25 either way is almost irrelevant. These prices are all "blue light specials", and with a PR due out any day now(or so they say...[I'll believe that when I see it]), I wouldn't want to be left out...
I can't post the chart right now, as my image hosting site is acting like RB was today, will post it when able to...
BTW, thanks for the compliment, it was a rather lucky call wasn't it...and to all that said 2.50 was support, they were right on also, on a closing price basis...GLTA Longs...
EP--APYM played out better than expected...
For a three day consolodation in an uptrend. Low float--eratic moves...
I'm staying LONG...Their CEO has a big Conference this Thursday:
Posted by: AVATAR270
In reply to: None Date:3/22/2005 4:53:14 PM
Post #of 47
Great day to be an APYM stockholder. Gotta love the low float that forces such powerful upsurges in PPS. Below is the itinerary for the Thursday Small Cap summit APYM will be atending:
Wall Street Reporter Magazine Hosting Micro-Cap Investors Summit III on March 24, 2005 in New York City
NEW YORK
Wall Street Reporter Magazine
Jack Marks, (212) 363-2600 ext 260
jmarks@wallstreetreporter.com
or
For Sponsorship & Speaking Opportunities, contact:
German de la Roche, (212)-363-2600 ext 222
german@wallstreetreporter.com
Wall Street Reporter Magazine will be hosting its third annual "Micro-Cap Investor's Summit" on March 24, in New York City. The Micro-Cap Investors Summit offers fund managers and analysts an unparalleled opportunity to gain insight into new trends and investment opportunities in the micro-cap marketplace.
The Summit will open with the "Smart Money Roundtable", a panel of top micro-cap experts who will share their insights, investment strategies and favorite stock picks - and pans - with attendees. The Smart Money Roundtable speakers will include:
-Tobin Smith, Founder, CHANGE WAVE RESEARCH
-Thom Waye, Managing Director, SIGMA CAPITAL
-David Grin, Managing Partner, LAURUS FUNDS
-Jack Marks, Publisher, WALL STREET REPORTER MAGAZINE
Following the roundtable, CEOs of seven up-and-coming micro-cap companies will make investor presentations, including:
-- Novadel Pharma Inc. (AMEX:NVD)
Novadel is developing lingual spray delivery systems for OTC and prescription drugs. CEO Gary Shangold will discuss Novadel's new partnership deals and the profit potential of the company's technology platform.
-- Small World Kids, Inc. (OTCBB:SWKD)
This fast growing toy company forecasts sales of $34 million in 2005. CEO Debra Fine will present an inside look at the company's hot new product lines, recent acquisitions, and her plans for future growth.
-- Asia Payment Systems, Inc. (OTCBB:APYM)
Asia Payment Systems is rapidly building a third-party credit card processing network in China and throughout Asia. The growth of China credit card transactions over the next 10 years will be massive and unprecedented in terms of scope and demand for processing infrastructure. CEO Matt Mecke will reveal Asia Payment Systems' strategy for capitalizing on this opportunity.
-- MobilePro Corp. (OTCBB:MOBL)
MobilePro just closed on a series of acquisitions which put it on track to $100+ million in revenues this year. MobilePro CEO Jay Wright will give a complete look at this wireless technology and broadband telecom company's exciting prospects for the months ahead.
-- ICOA Inc. (OTCBB:ICOA)
With revenues up more than 360% in 2004, ICOA is moving aggressively toward its goal of being the national leader in Wi-Fi networks and services. ICOA's President, Rick Schiffmann, will discuss his company's recent news and plans for WiMax and VoIP opportunities.
-- Opthalmic Imaging Systems, Inc. (OTCBB:OISI)
This company is a leading provider of ophthalmic digital imaging systems, and recently reported its 12th consecutive quarter of solid profits. Opthalmic Imaging will explain how a recent financing and exciting new product launches will impact growth.
ABOUT WALL STREET REPORTER:
Wall Street Reporter's Micro-Cap Investors Summit has an unparalleled reputation as a forum for emerging growth companies to present their businesses and strategies to the investment community. Companies presenting at the Summits benefit from increased investor awareness, as well as capital access and business development opportunities.
Attendees at the Micro-Cap Investors Summit include leading fund managers, analysts, investment banking professionals, as well as sophisticated individual investors.
Wall Street Reporter Magazine (Est. 1843) is a leading financial media company with online, print and event properties, connecting investors with worthwhile public companies.
To register for Micro-Cap Investors Summit: www.wallstreetreporter.com/mis
The foregoing is for informational purposes only and is not to be construed as an offer to sell or a solicitation to buy any securities mentioned in this press release.
This should really help to get the word out.
What A Day!...
I think we finally hit "THE" Bottom today...
The volume was big enough to make this call.
A good PR before the end of the month/quarter will confirm this, the sooner the better IMO...
GLTA Longs
APYM--YES!!!!!!!!!!!!!!!!!!!
I don't know what's going on, but I LIKE IT!!!
Look at that volume coming in...
Awesome NEWS out
Press Release Source: CytRx Corporation
CytRx Announces Phase I HIV Vaccine Clinical Trial Enrollment Completion
Tuesday March 22, 8:30 am ET
- Trial Enrollment Completed Six Months Ahead of Schedule -
LOS ANGELES, March 22 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR - News), Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) today announced the completion of enrollment of healthy volunteers in a three-arm Phase 1 clinical trial for a novel HIV DNA vaccine.
The primary objective of the Phase 1 clinical trial is to determine the safety and tolerability of different dosages and routes of administration of the DNA vaccine, and a fixed dosage and route of administration of an HIV protein boost. The vaccine strategy is to assess in human volunteers whether a DNA vaccine with a protein boost can stimulate both antibody and T-cell immune responses to the virus as previously demonstrated in animal models. To date, the vaccine has been well tolerated in humans.
"We reached this significant recruitment milestone six months ahead of our internal timetable" stated Steven A. Kriegsman, president and chief executive officer of CytRx. "We had previously announced that dosing would be completed by the end of 2005. Based on clinical investigators' efforts at UMMS to quickly complete enrollment, we now expect dosing to be completed by the end of July 2005, six months ahead of schedule."
CytRx, ABL and UMMS anticipate that preliminary safety, tolerability and limited immunogenicity data from this trial will be presented by the clinical investigators later this year.
"It is our hope that the results from this clinical trial will provide useful information regarding the immune response to this DNA vaccination as well as the effect of using protein as a vaccine boost," said Jeff Kennedy, M.D., assistant professor of medicine at UMMS and the principal investigator of the clinical trial.
The trial consists of three groups: Group A received the DNA vaccine intradermally, and Groups B and C received the DNA vaccine intramuscularly, with Group C receiving a six fold higher DNA dose compared with Groups A and B. This trial is designed to test the ability of different routes of administration and doses of the vaccine on immune responses to the antigens incorporated in the vaccine. Participants are monitored at regular intervals for adverse events as well as antibody responses and cell-mediated immune responses, which are the ability of the vaccine to cause the host to produce T-cells that kill HIV-infected cells. It is projected that Groups A and B will complete the five inoculations required by the protocol by May of this year and data from on-going assays of immune response are planned to be available in the third quarter of 2005. Group C is projected to complete DNA vaccination requirements in the third quarter of 2005.
The HIV vaccine formulation created by researchers at UMMS and ABL is a polyvalent vaccine based on multiple strains of HIV collected directly from infected people living in different parts of world, representing five different strains of the virus. The secondary objectives of the trial will test whether the approach can generate cross-clade anti-HIV immune response in humans. The vaccine contains elements from selected HIV genes, not the live virus and, therefore, individuals receiving inoculations cannot get HIV from the vaccine.
The HIV vaccine is exclusively licensed to CytRx by UMMS and ABL. To date, the HIV vaccine project has been funded under a five-year HIV Vaccine Design and Development Team contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
ABOUT ADVANCED BIOSCIENCE LABORATORIES
Advanced BioScience Laboratories, Inc. (ABL) located in Kensington Md., is a biomedical research, development and manufacturing company focusing on human retroviral diseases. ABL has been a leader in HIV-1 research for more than two decades and has been involved in the development of methods to both prevent and treat HIV-1 infection.
ABOUT THE UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $153 million in research funding annually, 80% of which comes from federal funding sources. Research funding enables UMMS scientists to explore human disease from the molecular level to large-scale clinical trials. Basic and clinical research leads to new approaches for diagnosis, treatment and prevention of disease. Visit www.umassmed.edu for additional information.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company, based in Los Angeles with a subsidiary in Worcester, Mass. The company is engaged in the development of products, primarily in the area of small molecules and ribonucleic acid interference (RNAi), in a variety of therapeutic categories. In October 2004, the company acquired three clinical stage compounds and a library of 500 small molecule drug candidates from Biorex Research & Development Company. The company has a broad-based strategic alliance with the University of Massachusetts Medical School to develop novel compounds in the areas of ALS, obesity, type 2 diabetes and CMV using RNAi technology. CytRx also licensed from UMMS the rights to a DNA-based HIV vaccine technology currently in a Phase I clinical trial. The company also has a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. For more information, visit CytRx's Web site at www.cytrx.com.
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of CytRx's diabetes, obesity, CMV and ALS research, the need for future clinical testing of any RNAi-based products and small molecules that may be developed by CytRx, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities for the products acquired from Biorex and other products and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for CytRx's RNAi technology or small molecules, CytRx's need for additional capital to fund its ongoing working capital needs, including ongoing research and development expenses related to the drugs purchased from Biorex, risks relating to the enforceability of any patents covering CytRx's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for CytRx's products. Additional uncertainties and risks are described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
GLTA
CYTR--HIV Vaccine Enters Phase I Trials...
Press Release Source: CytRx Corporation
CytRx Announces Phase I HIV Vaccine Clinical Trial Enrollment Completion
Tuesday March 22, 8:30 am ET
- Trial Enrollment Completed Six Months Ahead of Schedule -
LOS ANGELES, March 22 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR - News), Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) today announced the completion of enrollment of healthy volunteers in a three-arm Phase 1 clinical trial for a novel HIV DNA vaccine.
The primary objective of the Phase 1 clinical trial is to determine the safety and tolerability of different dosages and routes of administration of the DNA vaccine, and a fixed dosage and route of administration of an HIV protein boost. The vaccine strategy is to assess in human volunteers whether a DNA vaccine with a protein boost can stimulate both antibody and T-cell immune responses to the virus as previously demonstrated in animal models. To date, the vaccine has been well tolerated in humans.
"We reached this significant recruitment milestone six months ahead of our internal timetable" stated Steven A. Kriegsman, president and chief executive officer of CytRx. "We had previously announced that dosing would be completed by the end of 2005. Based on clinical investigators' efforts at UMMS to quickly complete enrollment, we now expect dosing to be completed by the end of July 2005, six months ahead of schedule."
CytRx, ABL and UMMS anticipate that preliminary safety, tolerability and limited immunogenicity data from this trial will be presented by the clinical investigators later this year.
"It is our hope that the results from this clinical trial will provide useful information regarding the immune response to this DNA vaccination as well as the effect of using protein as a vaccine boost," said Jeff Kennedy, M.D., assistant professor of medicine at UMMS and the principal investigator of the clinical trial.
The trial consists of three groups: Group A received the DNA vaccine intradermally, and Groups B and C received the DNA vaccine intramuscularly, with Group C receiving a six fold higher DNA dose compared with Groups A and B. This trial is designed to test the ability of different routes of administration and doses of the vaccine on immune responses to the antigens incorporated in the vaccine. Participants are monitored at regular intervals for adverse events as well as antibody responses and cell-mediated immune responses, which are the ability of the vaccine to cause the host to produce T-cells that kill HIV-infected cells. It is projected that Groups A and B will complete the five inoculations required by the protocol by May of this year and data from on-going assays of immune response are planned to be available in the third quarter of 2005. Group C is projected to complete DNA vaccination requirements in the third quarter of 2005.
The HIV vaccine formulation created by researchers at UMMS and ABL is a polyvalent vaccine based on multiple strains of HIV collected directly from infected people living in different parts of world, representing five different strains of the virus. The secondary objectives of the trial will test whether the approach can generate cross-clade anti-HIV immune response in humans. The vaccine contains elements from selected HIV genes, not the live virus and, therefore, individuals receiving inoculations cannot get HIV from the vaccine.
The HIV vaccine is exclusively licensed to CytRx by UMMS and ABL. To date, the HIV vaccine project has been funded under a five-year HIV Vaccine Design and Development Team contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
ABOUT ADVANCED BIOSCIENCE LABORATORIES
Advanced BioScience Laboratories, Inc. (ABL) located in Kensington Md., is a biomedical research, development and manufacturing company focusing on human retroviral diseases. ABL has been a leader in HIV-1 research for more than two decades and has been involved in the development of methods to both prevent and treat HIV-1 infection.
ABOUT THE UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $153 million in research funding annually, 80% of which comes from federal funding sources. Research funding enables UMMS scientists to explore human disease from the molecular level to large-scale clinical trials. Basic and clinical research leads to new approaches for diagnosis, treatment and prevention of disease. Visit www.umassmed.edu for additional information.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company, based in Los Angeles with a subsidiary in Worcester, Mass. The company is engaged in the development of products, primarily in the area of small molecules and ribonucleic acid interference (RNAi), in a variety of therapeutic categories. In October 2004, the company acquired three clinical stage compounds and a library of 500 small molecule drug candidates from Biorex Research & Development Company. The company has a broad-based strategic alliance with the University of Massachusetts Medical School to develop novel compounds in the areas of ALS, obesity, type 2 diabetes and CMV using RNAi technology. CytRx also licensed from UMMS the rights to a DNA-based HIV vaccine technology currently in a Phase I clinical trial. The company also has a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. For more information, visit CytRx's Web site at www.cytrx.com.
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of CytRx's diabetes, obesity, CMV and ALS research, the need for future clinical testing of any RNAi-based products and small molecules that may be developed by CytRx, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities for the products acquired from Biorex and other products and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for CytRx's RNAi technology or small molecules, CytRx's need for additional capital to fund its ongoing working capital needs, including ongoing research and development expenses related to the drugs purchased from Biorex, risks relating to the enforceability of any patents covering CytRx's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for CytRx's products. Additional uncertainties and risks are described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
I think we close positive today...
Awesome NEWS out
Press Release Source: CytRx Corporation
CytRx Announces Phase I HIV Vaccine Clinical Trial Enrollment Completion
Tuesday March 22, 8:30 am ET
- Trial Enrollment Completed Six Months Ahead of Schedule -
LOS ANGELES, March 22 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR - News), Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) today announced the completion of enrollment of healthy volunteers in a three-arm Phase 1 clinical trial for a novel HIV DNA vaccine.
The primary objective of the Phase 1 clinical trial is to determine the safety and tolerability of different dosages and routes of administration of the DNA vaccine, and a fixed dosage and route of administration of an HIV protein boost. The vaccine strategy is to assess in human volunteers whether a DNA vaccine with a protein boost can stimulate both antibody and T-cell immune responses to the virus as previously demonstrated in animal models. To date, the vaccine has been well tolerated in humans.
"We reached this significant recruitment milestone six months ahead of our internal timetable" stated Steven A. Kriegsman, president and chief executive officer of CytRx. "We had previously announced that dosing would be completed by the end of 2005. Based on clinical investigators' efforts at UMMS to quickly complete enrollment, we now expect dosing to be completed by the end of July 2005, six months ahead of schedule."
CytRx, ABL and UMMS anticipate that preliminary safety, tolerability and limited immunogenicity data from this trial will be presented by the clinical investigators later this year.
"It is our hope that the results from this clinical trial will provide useful information regarding the immune response to this DNA vaccination as well as the effect of using protein as a vaccine boost," said Jeff Kennedy, M.D., assistant professor of medicine at UMMS and the principal investigator of the clinical trial.
The trial consists of three groups: Group A received the DNA vaccine intradermally, and Groups B and C received the DNA vaccine intramuscularly, with Group C receiving a six fold higher DNA dose compared with Groups A and B. This trial is designed to test the ability of different routes of administration and doses of the vaccine on immune responses to the antigens incorporated in the vaccine. Participants are monitored at regular intervals for adverse events as well as antibody responses and cell-mediated immune responses, which are the ability of the vaccine to cause the host to produce T-cells that kill HIV-infected cells. It is projected that Groups A and B will complete the five inoculations required by the protocol by May of this year and data from on-going assays of immune response are planned to be available in the third quarter of 2005. Group C is projected to complete DNA vaccination requirements in the third quarter of 2005.
The HIV vaccine formulation created by researchers at UMMS and ABL is a polyvalent vaccine based on multiple strains of HIV collected directly from infected people living in different parts of world, representing five different strains of the virus. The secondary objectives of the trial will test whether the approach can generate cross-clade anti-HIV immune response in humans. The vaccine contains elements from selected HIV genes, not the live virus and, therefore, individuals receiving inoculations cannot get HIV from the vaccine.
The HIV vaccine is exclusively licensed to CytRx by UMMS and ABL. To date, the HIV vaccine project has been funded under a five-year HIV Vaccine Design and Development Team contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
ABOUT ADVANCED BIOSCIENCE LABORATORIES
Advanced BioScience Laboratories, Inc. (ABL) located in Kensington Md., is a biomedical research, development and manufacturing company focusing on human retroviral diseases. ABL has been a leader in HIV-1 research for more than two decades and has been involved in the development of methods to both prevent and treat HIV-1 infection.
ABOUT THE UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $153 million in research funding annually, 80% of which comes from federal funding sources. Research funding enables UMMS scientists to explore human disease from the molecular level to large-scale clinical trials. Basic and clinical research leads to new approaches for diagnosis, treatment and prevention of disease. Visit www.umassmed.edu for additional information.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company, based in Los Angeles with a subsidiary in Worcester, Mass. The company is engaged in the development of products, primarily in the area of small molecules and ribonucleic acid interference (RNAi), in a variety of therapeutic categories. In October 2004, the company acquired three clinical stage compounds and a library of 500 small molecule drug candidates from Biorex Research & Development Company. The company has a broad-based strategic alliance with the University of Massachusetts Medical School to develop novel compounds in the areas of ALS, obesity, type 2 diabetes and CMV using RNAi technology. CytRx also licensed from UMMS the rights to a DNA-based HIV vaccine technology currently in a Phase I clinical trial. The company also has a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. For more information, visit CytRx's Web site at www.cytrx.com.
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of CytRx's diabetes, obesity, CMV and ALS research, the need for future clinical testing of any RNAi-based products and small molecules that may be developed by CytRx, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities for the products acquired from Biorex and other products and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for CytRx's RNAi technology or small molecules, CytRx's need for additional capital to fund its ongoing working capital needs, including ongoing research and development expenses related to the drugs purchased from Biorex, risks relating to the enforceability of any patents covering CytRx's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for CytRx's products. Additional uncertainties and risks are described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Welcome to the board ease2002!
Good Call! No reason I can see for this move up today on the highest volume since 2/11/05--http://finance.yahoo.com/q/hp?s=CYTR...
Pretty big gap up at the open too, without News of any kind that I can find...Someone must know something we don't...Unfortunatly, I feel it will have to go back and fill the gap, though I could be wrong on this...
Do you have a position in CYTR? It's kind of quiet on this board, I hope something happens soon to give us a reason to cheer.
Good Luck To You, in all you do...
CPTC--If it closes below the 200MA...
I'm pretty sure we spike down to 2.25 JMHO
I'm going to try to pick the "bottom" here...
Hope I don't get smelly fingers...
CPTC--Here's the bottom as I see it...
What a shame--a 100% round-trip...
Only thing to save this from happening is a Good PR...
Maybe one before the bell tomorrow??? They usually come out on Tuesdays...
More News Out Today:
Press Release Source: Asia Payment Systems, Inc.
Asia Pay Launches Shanghai Data Centre and SCRC Telecom Project Kickoff
Thursday March 17, 7:45 am ET
SEATTLE and SHANGHAI, March 17 /PRNewswire-FirstCall/ -- Asia Payment Systems, Inc. (OTC Bulletin Board: APYM - News) announced today the launch of the Shanghai Data Centre to serve as the hub for payment processing and credit bureau systems in China.
In conjunction with SCRC Telecom, Asia Pay has established a Data Centre in Shanghai through which Asia Payment Systems applications will be deployed to the China customer base. In addition to the establishment of this Shanghai Data Centre, Asia Pay has begun deploying technical and project management resources to begin the day-to-day project implementations that have been announced previously between SCRC Telecom and Asia Payment Systems.
Ten leading financial institutions were represented at the Data Centre signing ceremony held in Shanghai March 15th, including Industrial and Commercial Bank of China (ICBC, http://www.icbc.com.cn), China Construction Bank (CCB, http://www.ccb.cn), and China Minsheng Bank (China's first private bank, http://www.cmbc.cn). These financial institutions are some of the largest banks in China. Strong interest was received from several financial institutions for Asia Pay to set up card programs for their larger merchants. Asia Pay believes that the company's experience in China positions Asia Pay to capitalize on the growing need for world-class bankcard-processing services throughout China.
Matt Mecke, President & CEO of Asia Pay, announced, "We are very happy to announce the launch of our Shanghai Data Centre with support from SCRC Telecom. This first full China Data Centre will allow Asia Payment Systems to build out and deploy our services and applications to the market in China. We continue to see strong demand for our services and expertise, and we look forward to increasing the staff and other resources to support the full build- out and use of this Shanghai Data Centre in the future."
The company's proprietary system processes domestic and international debit cards and credit cards using a combination of proprietary advanced technologies and rigorous security procedures. Asia Pay aims to become a leading provider of world-class third-party processing services to bankcard- accepting merchants and issuers throughout Asia. Asia Pay is positioned to provide much-needed processing infrastructure during the coming decade of exponential growth of credit card transactions in China and other markets in Asia.
If 3.22 falls, we better strap our hard hats on again...
It's a sad day in CPTC land, and yes, "Flushed" is an appropriate description for todays action...The hoax(?) of the award probably isn't helping, then we get great news of a new installation and we dump the next two days??? Wasn't that substation in AZ the one the govt. forced to upgrade? And they used ACCC, setting a precedent IMO...I just don't get it...
CPTC IS DUMPING TODAY! EOM
APYM--May make it's grand opening in China today at a Duty Free Store, if I'm not mistaken. Keep an eye out for News, when it comes out I expect a Boosh to nearly 2.00........
UGLY CHART:
If 3.55 (the low of 3/2/05) falls, time to get the hard hats on again...
Two NICE Charts:
BIPH--Another Nice Chart=Gonna Boosh!
EZEN--NICE Looking chart:
beigledog...
Because the test is confined in a sub-station,I'd bet the farm we gave the cable away. Though I too wish they had told us what size cable it was... Did one piece replace two, or a banded cable? How long of a piece it was, and other information, which I find lacking in this PR...
As far as "test installations" go--IMO--the more the merrier!
We have Holland, MI for cold weather testing and now Phoenix for high temp testing. All test installations are a Good thing for CTC, and all according to the master plan IMO.
Good management! Go CTC! GLTA
FDEI CEO Audio Interview at Wallstreet.net
Press Release Source: Wall Street Network
WallSt.net Airing Exclusive Audio Interviews With FDEI, URBN, RGS and PETC
Tuesday March 15, 7:00 am ET
NEW YORK, March 15 /PRNewswire/ -- Dan Hodges, CEO of Fidelis Energy, Inc. (OTC Bulletin Board: FDEI - News) recently granted WallSt.net an exclusive audio interview profiling the company. Interview highlights include discussions on the following topics:
-- the Company's 100% hit rate
-- the possibility of net revenues between $12,000 and $14,000 a day
-- national market listing
-- financials
-- overview of operations
-- upcoming milestones
To hear the interview in its entirety, and to read an in-depth report on the company, visit http://wallst.net/superstock/FDEI/fdei.html.
John Kyees, Chief Financial Officer for Urban Outfitters, Inc. (Nasdaq: URBN - News) recently granted Wall Street Network an exclusive audio interview profiling the company. Interview highlights include discussions on the following topics:
-- growth potential
-- target demographics/demographic trends
-- cash position
-- expansion plans
-- metrics for gauging the company's success
-- upcoming milestones
Paul Finkelstein, Chairman, President and CEO of Regis Corp. (NYSE: RGS - News) recently granted Wall Street Network an exclusive audio interview profiling the company. Interview highlights include discussions on the following topics:
-- recent acquisitions
-- market share goals
-- partnership with American Express
-- organic growth vs. M & A
-- upcoming milestones
Rodney Carter, Chief Financial Officer for Petco Animal Supplies, Inc. (Nasdaq: PETC - News) recently granted Wall Street Network an exclusive audio interview profiling the company. Interview highlights include discussions on the following topics:
-- industry trends supporting the company's prospects for growth
-- management bios
-- financial and strategic highlights from Q4 and Fiscal '04
-- animal rights activists
-- upcoming milestones
To hear the interviews in their entirety, visit www.wallst.net. The interviews can be accessed by locating the respective company's ticker symbol under the exchange on which it trades, or by entering the respective company's ticker symbol in the Audio Search window.
About Wall Street Network
Wall Street Network is owned and licensed by Wall Street Direct, Inc. All material herein was prepared by Digital Wall Street, Inc., a multimedia provider of original, insightful commentary and news from North America's leading publicly traded companies giving a direct link to the management of today's fastest-growing companies through encompassing executive interviews and sector seminars. The company provides a free service to consumers, and a paid, premium monthly subscription to its members. Digital Wall Street, Inc. has received twenty five thousand dollars from a third party for press and advertising materials for FDEI, and has received fifty thousand dollars for a separate contract from a third party for press and advertising materials for FDEI. For a complete list of our business relationships, visit www.wallst.net/disclaimer.asp.
Contact
Nick Iyer
WallSt.net
800 4 WALL ST
--------------------------------------------------------------------------------
Source: Wall Street Network
BIPH News Today:
Press Release Source: Shazamstocks.com; Biophan Technologies, Inc.
Shazamstocks.com Announces Profile Launch of Biophan Technologies, Inc.
Tuesday March 15, 8:00 am ET
GRANGER, Ind., March 15, 2005 (PRIMEZONE) -- Ken Weiner, Publisher of Shazamstocks.com, today announced profile coverage of Biophan Technologies, Inc. (OTC BB:BIPH.OB - News). The Profile is a comprehensive look at the company's growth imitative. You can view the complete profile at http://profiles.shaazamstocks.com/biph/index.htm
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 108 U.S. patents, licenses, or applications. This total includes 32 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit http://www.biophan.com.
About Shazamstocks.com
Shazamstocks.com publishes profiles on up and coming publicly traded companies. Shazamstocks.com is one of the nation's top Internet destinations for small cap stock information. To feature your company, please call Ken Weiner, our Publisher at (574) 273-8755 or email editor@shazamstocks.com.
Disclosure: Shazamstocks.com has been compensated by a third party fifteen thousand dollars for this profile. Details can be found at http://www.shazamstocks.com